US Bancorp’s Zealand Pharma A/S American Depositary Shares ZEAL Stock Holding History

US Bancorp’s Portfolio ZEAL Stock Details ZEAL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-509	Closed	-$7K	–	4300
2022 Q2	$7K	Hold	509	–	–	﹤0.01%	3500
2022 Q1	$8K	Sell	509 -40	-7%	-$675	﹤0.01%	3487
2021 Q4	$12K	Sell	549 -12	-2%	-$305	﹤0.01%	3373
2021 Q3	$17K	Sell	561 -10	-2%	-$301	﹤0.01%	3225
2021 Q2	$17K	Buy	571 +350	+158%	+$10.9K	﹤0.01%	3233
2021 Q1	$7K	Buy	221 +7	+3%	+$236	﹤0.01%	3433
2020 Q4	$7K	Sell	214 -46	-18%	-$1.73K	﹤0.01%	3326
2020 Q3	$10K	Hold	260	–	–	﹤0.01%	3100
2020 Q2	$9K	Buy	260 +23	+10%	+$817	﹤0.01%	3142
2020 Q1	$8K	Buy	+237	New	+$8.26K	﹤0.01%	3119

Other funds holding ZEAL

TimeScale Financial Danvers, Massachusetts $463M AUM 12.48% 1-Year Est. Return

US Bancorp's ZEAL Position: Q3 2022 in Review

US Bancorp sold out of Zealand Pharma A/S American Depositary Shares (ZEAL) in Q3 2022, closing a stake of 509 shares — an estimated $7K sold.

US Bancorp first reported a position in ZEAL in Q1 2020 and held it in 10 quarters. The position peaked at $17K in Q3 2021. 1 fund tracked by Wall St. Rank holds ZEAL as of Q3 2022.

US Bancorp reported no remaining Zealand Pharma A/S American Depositary Shares position as of Q3 2022 after selling out during the quarter.
US Bancorp sold 509 Zealand Pharma A/S American Depositary Shares shares in Q3 2022, an estimated $7K.
US Bancorp first reported a position in Zealand Pharma A/S American Depositary Shares in Q1 2020 and held it in 10 quarters.
US Bancorp's Zealand Pharma A/S American Depositary Shares position peaked at $17K in Q3 2021.
1 fund tracked by Wall St. Rank held Zealand Pharma A/S American Depositary Shares as of Q3 2022.

Based on US Bancorp's 13F filing for Q3 2022, filed 27 Oct 2022.